Brief: Theratechnologies Receives FDA Approval For EGRIFTA WR (Tesamorelin F8) To Treat Excess Visceral Abdominal Fat In Adults With HIV And Lipodystrophy
25/03/2025 21:47
March 25 (Reuters) - Theratechnologies Inc TH.TO: THERATECHNOLOGIES RECEIVES FDA APPROVAL FOR EGRIFTA WR™ (TESAMORELIN F8) TO TREAT EXCESS VISCERAL ABDOMINAL FAT IN ADULTS WITH HIV AND LIPODYSTROPHY THERATECHNOLOGIES INC: EGRIFTA WR WILL BE MANUFACTURED AT A NEW, U.S.-BASED CONTRACT DRUG MANUFACTURING ORGANIZATION Source text: ID:nGNX8jmc4d Further company coverage: TH.TO ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Theratechnologies
See all newsBrief: Theratechnologies Receives Final Court Approval On To Be Acquired By Future Pak
Brief: Theratechnologies Inc - Iss And Glass Lewis Recommend Voting 'For' Future Pak Arrangement
Canadian drugmaker Theratechnologies beats Q2 revenue estimates on strong demand
Brief: Theratechnologies Enters Into Definitive Agreement To Be Acquired By Cb Biotechnology, An Affiliate Of Future Pak
Brief: Theratechnologies Inc Decided To Further Evaluate Potential Sale Of Company Through An Open And Non-Exclusive Process